Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma

Mantopoulos, Dimosthenis; Kendra, Kari; Letson, Alan D.; Cebulla, Colleen M.

doi:10.1001/jamaophthalmol.2015.1128

Cited by 53 publications

(25 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rarely described, retinal involvement such as bilateral multifocal choroidal neovascularization may potentially result in retinal or preretinal hemorrhages, retinal edema, and retinal detachment similar to age‐related macular degeneration . In addition, retinal involvement has also been described in two patients suspected of having Vogt‐Koyanagi‐Harada syndrome .…”

Section: Episcleritis/uveitis and Disorders Of The Orbitmentioning

confidence: 99%

“…Selten wird von einer Beteiligung der Retina berichtet wie eine bilaterale multifokale choroidale Neovaskularisation mit der möglichen Folge von retinalen oder präretinalen Hämorrhagien, Ödemen der Retina und einer Netzhautablösung mit Ähnlichkeiten zur altersbedingten Makuladegeneration [ 39,40 ] . Ferner trat eine retinale Beteiligung bei zwei Patienten im Rahmen eines vermuteten Vogt-Koyanagi-Harada-Syndroms auf [ 41,42 ] .…”

Section: Episkleritis/uveitis Und Erkrankungen Der Orbitaunclassified

See 1 more Smart Citation

Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma

Kähler

Hassel

Heinzerling

et al. 2016

J Deutsche Derma Gesell

172

View full text Add to dashboard Cite

SummaryCTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015. Immune responses thus induced and enhanced inevitably entail autoimmune phenomena, affecting various organs to varying degrees. Knowledge of these side effects is crucial with regard to prevention and management by treating physicians. Typically occurring early on and presenting with pronounced and persistent diarrhea, colitis represents a major and severe side effect. Other immune-mediated disorders include dermatitis, hypophysitis, thyroiditis, hepatitis, iridocyclitis as well as other less common autoimmune phenomena. Early recognition and initiation of treatment can reduce risks and sequelae for patients. This review describes the mechanisms of action of immune checkpoint blockade as well as its clinical effects in metastatic melanoma, with a detailed focus on the spectrum of adverse events and their therapeutic management.

show abstract

Section: Episcleritis/uveitis and Disorders Of The Orbitmentioning

confidence: 99%

Section: Episkleritis/uveitis Und Erkrankungen Der Orbitaunclassified

Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma

Kähler

Hassel

Heinzerling

et al. 2016

J Deutsche Derma Gesell

172

View full text Add to dashboard Cite

show abstract

“…Recently, Mantopoulos et al [26] and Crews et al [27] published two cases in which bilateral choroidopathy and serous retinal detachments occurred due to choroidal vascular injury, during ipilimumab treatment for cutaneous melanoma. The cases have similarities to the case of ipilimumab-induced VKH syndrome; however, patients had significantly less intraocular inflammation, no symptoms of VKH syndrome and no hyperfluorescence on fluorescein angiography.…”

Section: Ocular and Orbital-side-effects Of Checkpoint Inhibitorsmentioning

confidence: 99%

Ocular and orbital side-effects of checkpoint inhibitors: a review article

Antoun

Titah

Cochereau

2016

Current Opinion in Oncology

122

101

View full text Add to dashboard Cite

show abstract

“…They can be almost the same as typical VKH, but untypical clinical features are more common . For example, incomplete symptoms and signs might occur in VKH‐like syndrome, such as patients having no symptoms of meningism, hearing loss or vitiligo . Furthermore, differences in the sequence of symptoms and signs may occur.…”

Section: Vogt‐koyanagi‐harada Like Syndromementioning

confidence: 99%

“…17 For example, incomplete symptoms and signs might occur in VKH-like syndrome, such as patients having no symptoms of meningism, hearing loss or vitiligo. 19 Furthermore, differences in the sequence of symptoms and signs may occur. Patients might have no prodromal stage and the vitiligo might occur before the ocular signs.…”

Section: Symptoms and Signsmentioning

confidence: 99%

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

et al. 2020

View full text Add to dashboard Cite

The increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune‐related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been largely ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases. Key points This review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor‐related ocular adverse events.

show abstract

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma

Cited by 53 publications

References 7 publications

Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma

Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma

Ocular and orbital side-effects of checkpoint inhibitors: a review article

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Contact Info

Product

Resources

About